Back to Search Start Over

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Authors :
Donald E. Ingber
H. Feldmann
Kyle Rosenke
César Muñoz-Fontela
Joana Rocha-Pereira
Pierre Stéphane Gsell
Matthew B. Frieman
Simon G. P. Funnell
Kai Dallmeier
Suzanne J.F. Kaptein
E. de Wit
Johan Neyts
Leen Delang
R. Le Grand
Pauline Maisonnasse
W. E. Dowling
G. A. Hamilton
C. M. Coleman
Public Health England [London]
Coalition for Epidemic Preparedness Innovations [Washington, DC, États-Unis] (CEPI)
Bernhard Nocht Institute for Tropical Medicine - Bernhard-Nocht-Institut für Tropenmedizin [Hamburg, Germany] (BNITM)
Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)
Harvard University [Cambridge]
Emulate, Inc. [Boston, MA, États-Unis]
Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)
National Institute of Health [Hamilton, MT, États-Unis]
Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB)
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
University of Maryland School of Medicine
University of Maryland System
University of Nottingham, UK (UON)
D.E. Ingber acknowledges research funding from NIH NCATS UH3-HL-141797 and DARPA under Cooperative Agreements HR00111920008 and HR0011-20-2-0040. P. Maisonnass acknowledges financial support from REACTing, the National Research Agency (ANR-AM-CoV-Path), the European Union’s Horizon 2020 (H2020) research and innovation programme Fight-nCov (grant No. 101003555), the European Union IMI2 programme CARE (grant No. 101005077), the European Infrastructure TRANSVAC2 (grant No. 730964) and virus stock was obtained through the EVAg platform (https://www.european-virus-archive.com/) funded by H2020 (Grant No. 653316). The Inserm Infectious Disease Models and Innovative Therapies research infrastructure (IDMIT) is supported by the 'Programme Investissements d’Avenir' (PIA), managed by the ANR under reference ANR-11-INBS-0008, the Fondation Bettencourt Schueller, the Region Ile-de-France and the Domaine d’Intérêt Majeur (DIM, Paris, France) 'One Health'. H. Feldmann acknowledges that the Laboratory of Virology was funded by the NIAID Intramural Research Programme
ANR-11-INBS-0008,IDMIT,Infrastructure nationale pour la modélisation des maladies infectieuses humaines(2011)
European Project: 653316,H2020,H2020-INFRAIA-2014-2015,EVAg(2015)
Harvard University
Bodescot, Myriam
Infrastructures - Infrastructure nationale pour la modélisation des maladies infectieuses humaines - - IDMIT2011 - ANR-11-INBS-0008 - INBS - VALID
European Virus Archive goes global - EVAg - - H20202015-04-01 - 2019-03-31 - 653316 - VALID
Source :
Nature Communications, Vol 11, Iss 1, Pp 1-4 (2020), Nature Communications, Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4253. ⟨10.1038/s41467-020-17907-w⟩, Nature Communications, 2020, 11 (1), pp.4253. ⟨10.1038/s41467-020-17907-w⟩
Publication Year :
2020
Publisher :
Nature Portfolio, 2020.

Abstract

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19. ispartof: NATURE COMMUNICATIONS vol:11 issue:1 ispartof: location:England status: published

Subjects

Subjects :
0301 basic medicine
General Physics and Astronomy
02 engineering and technology
Treatment failure
Mice
Cricetinae
Treatment Failure
lcsh:Science
Repurposing
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology
[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases
education.field_of_study
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases
Multidisciplinary
021001 nanoscience & nanotechnology
3. Good health
[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
0210 nano-technology
Coronavirus Infections
medicine.drug
Hydroxychloroquine
Primates
medicine.medical_specialty
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Science
Population
Pneumonia, Viral
Antiviral Agents
Models, Biological
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
Betacoronavirus
Animal disease models
medicine
Animals
Humans
Intensive care medicine
education
Pandemics
Extramural
business.industry
SARS-CoV-2
Comment
COVID-19
General Chemistry
COVID-19 Drug Treatment
Respiratory system models
030104 developmental biology
Preclinical research
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
lcsh:Q
business

Details

Language :
English
ISSN :
20411723
Volume :
11
Issue :
1
Database :
OpenAIRE
Journal :
Nature Communications
Accession number :
edsair.doi.dedup.....14560b8e4395d47e97fecb3e239be3c2

Tools

Authors Abstract Subjects Details